1.
Blood
; 142(26): 2327-2331, 2023 12 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37738563
RESUMO
ABSTRACT: In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.